B. Riley Securities Maintains Buy on Elicio Therapeutics, Lowers Price Target to $8

B. Riley Securities analyst Mayank Mamtani has maintained a 'Buy' rating on Elicio Therapeutics (NASDAQ: ELTX) but has reduced the price target from $27 to $8. This adjustment reflects a significant decrease in the expected valuation of the company.